Cargando…
Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro
BACKGROUND: The phosphoinositide-3-kinase (PI3K) pathway is the most commonly activated pathway in cancers due to mutations at multiple nodes and loss of PTEN. Furthermore, in endometrial cancer (EC), PI3K and RAS/RAF/MEK/MAPK (RAS/MAPK herein) pathway mutations frequently co-exist. We examined the...
Autores principales: | Aslan, Ozlem, Cremona, Mattia, Morgan, Clare, Cheung, Lydia W., Mills, Gordon B., Hennessy, Bryan T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807759/ https://www.ncbi.nlm.nih.gov/pubmed/29426295 http://dx.doi.org/10.1186/s12885-018-4035-0 |
Ejemplares similares
-
Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
por: Lee, Cha Len, et al.
Publicado: (2023) -
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib
por: O’Shea, John, et al.
Publicado: (2017) -
RPPAML/RIMS: A metadata format and an information management system for reverse phase protein arrays
por: Stanislaus, Romesh, et al.
Publicado: (2008) -
Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical Models
por: Zhong, Hua, et al.
Publicado: (2013) -
Correction: Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical Models
por: Zhong, Hua, et al.
Publicado: (2015)